Good point. I would guess it will take about 2 years to get Vimovo up to speed. The number for Treximet is for this year, The pipeline value was discounted to a current value. In two years Pozn should have one or two additional drugs ready for approval. The income from future drugs will not be split with a partner. So the only number that I did not discount was the Vimovo royalties. Lets apply a 25% haircut to bring the income value of Vimovo down from two years to one year. That gives a one year target of 56.33.
Market Data 
Markets 
AI
